



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

January 18, 2017

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Dear Sirs,

Sub: Granting of authority to the Company by AstraZeneca Pharma India Limited for certain rights in relation to identified injectable antibiotic products through a Delegation of Authority.

Pursuant to Regulation 30, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has entered into a Delegation of Authority with AstraZeneca Pharma India Limited ("AstraZeneca"), pursuant to which AstraZeneca has granted certain authority to the Company to conduct certain activities in India ("DoA"). The said Delegation of Authority is a result of a global agreement whereby Pfizer Inc. through its affiliates acquired from AstraZeneca PLC (through its affiliates) the development and commercial rights of their late-stage small molecule anti-infectives business. By way of this DoA, the Company has been granted the authority, *inter alia*, to carry out the activities of pricing and reimbursement negotiations, promotional, marketing, tendering, bidding, and distribution in relation to the identified injectable antibiotic products. Pursuant to this, Meronem IV Injection which is currently marketed in India by AstraZeneca is expected to be transitioned to the Company.

We request you to kindly take the same on record.

Thanking you,

For Pfizer Limited

Prajeet Nair
Company Secretary